scorecardresearchConcord Biotech Share Price Live NSE, BSE, Today - Concord Biotech Stock
Mintgenie
Asian Paints3,172.7052.70 (1.69%)
Axis Bank1,103.8029.15 (2.71%)
Bajaj Finance7,256.15131.25 (1.84%)
Bajaj Finserve1,679.354.55 (0.27%)
Bharti Airtel1,012.90-1.65 (-0.16%)
HCL Technologies1,339.80-0.50 (-0.04%)
HDFC Bank1,555.50-3.50 (-0.22%)
Hindustan Unilever2,563.2516.55 (0.65%)
ICICI Bank946.3511.15 (1.19%)
ITC449.9014.30 (3.28%)
Indusind Bank1,461.15-5.20 (-0.35%)
Infosys1,452.25-3.05 (-0.21%)
Kotak Mahindra Bank1,750.80-4.70 (-0.27%)
Larsen & Toubro3,189.9578.30 (2.52%)
Mahindra & Mahindra1,626.70-20.90 (-1.27%)
Maruti Suzuki India10,564.85-39.25 (-0.37%)
NTPC269.057.75 (2.97%)
Nestle India24,355.00137.80 (0.57%)
Power Grid Corporation Of India210.351.40 (0.67%)
Reliance Industries2,393.4517.05 (0.72%)
State Bank Of India571.857.15 (1.27%)
Sun Pharmaceutical Industries1,231.254.10 (0.33%)
Tata Consultancy Services3,509.6016.20 (0.46%)
Tata Motors705.70-0.55 (-0.08%)
Tata Steel129.952.00 (1.56%)
Tech Mahindra1,217.10-3.50 (-0.29%)
Titan Company3,488.55-3.40 (-0.10%)
Ultratech Cement9,039.1038.45 (0.43%)
Wipro407.70-5.55 (-1.34%)

Concord Biotech

BSE: 543960 | NSE: CONCORDBIO | ISIN: INE338H01029 | SECTOR:

₹1,305.40 -31.40 (-2.35%)

01 Dec 2023, 10:25 (IST)

  • Open

    1,337.05

  • High

    1,355.60

  • Low

    1,300.05

  • Prev Close

    1,336.80

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    136.57B

  • Volume

    9.21K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    1,305.40
View all metrics

Company Description

  • BSE

    543960

  • NSE

    CONCORDBIO

  • ISIN

    INE338H01029

Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. It manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. It also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The Company provides products in the critical care, immunology, nephrology, and transplant medicine segments.

Company Officers

  • Sudhir Vaid

    Executive Chairman of the Board, Managing Director

  • Ankur Vaid

    Chief Executive Officer, Joint Managing Director, Executive Director

  • Lalit Sethi

    Chief Financial Officer

  • Prakash Sajnani

    Compliance Officer, Company Secretary, Assistant Vice President - Finance

  • Devang Bhatt

    Vice President - Sales and Marketing, Head - Limbasi Plant - 3

  • Manoj Kumar

    Vice-President - Formulation Division and Head - Valthera Unit - 2

  • Sundeep Bengani

    General Manager - International Business Development, Formulation Division